Dublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Preclinical Imaging Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.
The Preclinical Imaging Market research report provides comprehensive analysis of a sector projected to reach USD 4.09 billion in 2026 and expand at a CAGR of 5.96% to USD 5.81 billion by 2032. It examines technologies, applications, end users, regional dynamics, and strategic developments shaping noninvasive imaging across drug discovery and translational research. The insights support market entry planning, technology investment decisions, and the identification of emerging growth opportunities.
Market Scope and Growth Drivers
Preclinical imaging enables noninvasive visualization of anatomy, physiology, metabolism, biodistribution, and treatment response in small-animal disease models. The market encompasses micro-CT, micro-MRI, PET, SPECT, optical imaging, ultrasound, photoacoustic systems, multimodal platforms, imaging probes, radiotracers, software, and contract imaging services.
Demand is driven by the need to improve drug discovery productivity, reduce late-stage clinical attrition, and generate reproducible in vivo evidence before first-in-human studies. Increasingly complex pipelines in oncology, neuroscience, cardiometabolic disease, inflammation, infectious disease, and cell and gene therapy are expanding the role of imaging in biomarker validation, pharmacokinetics, pharmacodynamics, toxicology, and longitudinal monitoring.
Transformative Technology Shifts
The market is moving from standalone instruments toward integrated, multimodal research ecosystems. PET/CT, SPECT/CT, PET/MRI, optical-CT, ultrasound-photoacoustic, and other hybrid workflows combine structural, functional, and molecular information within longitudinal studies. These capabilities can strengthen translational confidence while supporting the 3Rs principles through reduced animal use.
Adoption is also influenced by higher-resolution detectors, improved reconstruction, targeted probes, theranostic radiotracers, cloud-enabled image management, and standardized quantification. Laboratories increasingly prioritize reproducibility, regulatory-grade data integrity, and interoperable software. Understanding these shifts enables technology providers and research organizations to align product development with changing workflow requirements.
Artificial Intelligence Impact
Artificial intelligence is improving segmentation, registration, denoising, reconstruction, phenotyping, and quantitative biomarker extraction. AI-enabled workflows can reduce reader variability, accelerate high-throughput analysis, and enhance longitudinal comparisons in tumor burden assessment, neuroimaging, fibrosis modeling, and biodistribution studies.
Adoption is moving toward explainable AI, audit-ready analytics, validated datasets, and human-in-the-loop review. These approaches improve productivity while preserving scientific rigor and regulatory confidence.
Regional Market Insights
. North America leads through concentrated pharmaceutical R&D, biotechnology financing, federal research support, advanced academic centers, and specialized CRO capacity.
. Europe benefits from collaborative research networks, radiopharmaceutical expertise, and strong standards for reproducibility, animal welfare, and data integrity.
. Asia-Pacific is expanding rapidly as China, Japan, South Korea, India, Australia, and ASEAN markets invest in biotechnology, translational medicine, radiotracers, and advanced imaging infrastructure.
. Latin America is gaining traction through university hospitals and public research institutes, particularly in Brazil and Mexico.
. The Middle East is investing in academic medical centers, precision medicine, and healthcare innovation, while Africa presents emerging opportunities in infectious disease research and public health partnerships.
Regional comparisons provide practical guidance for prioritizing partnerships, distribution strategies, service expansion, and localized market entry.
Economic Group and Country Insights
ASEAN demand favors compact, cost-efficient systems and outsourced services, while GCC investment supports advanced oncology, metabolic disease, neurology, and radiopharmaceutical research. The European Union emphasizes standardized protocols and interoperable analytics. BRICS economies are expanding domestic pharmaceutical and biotechnology capabilities, while G7 markets remain central to premium systems, regulatory science, and radiotracer innovation.
The United States leads in infrastructure, financing, CRO specialization, and molecular imaging. Germany, France, the United Kingdom, Italy, and Spain maintain strong academic and pharmaceutical research ecosystems. China is scaling rapidly, India is expanding cost-efficient CRO capacity, Japan excels in precision instrumentation, South Korea is advancing digital imaging and biotechnology, and Australia offers established translational research networks.
Strategic Recommendations
Industry leaders should prioritize multimodal platforms, validated biomarkers, standardized protocols, and interoperable data systems connecting preclinical findings with clinical endpoints. Competitive advantage can be strengthened through modular systems, AI-assisted analytics, application-specific probes, remote services, and technical training.
Pharmaceutical, biotechnology, and CRO teams should align imaging endpoints with mechanism-of-action hypotheses early in study design. Partnerships involving radiochemistry laboratories, AI developers, animal model specialists, imaging core facilities, and regulatory consultants can mitigate execution risks and shorten timelines.
Key Takeaways from This Report
. The market is forecast to grow from USD 4.09 billion in 2026 to USD 5.81 billion by 2032.
. Multimodal imaging, AI-enabled quantification, targeted probes, and radiopharmaceutical innovation are central growth areas.
. Reproducibility, interoperability, and regulatory-grade data integrity increasingly influence purchasing decisions.
. North America remains the leading hub, while Asia-Pacific presents significant expansion potential.
. Strategic partnerships and application-focused solutions can accelerate adoption and strengthen translational outcomes.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 192 |
| Forecast Period | 2026 - 2032 |
| Estimated Market Value (USD) in 2026 | $4.09 Billion |
| Forecasted Market Value (USD) by 2032 | $5.81 Billion |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Preclinical Imaging Market, by Product
7.1. Introduction
7.2. Reagents
7.2.1. Bioluminescent Imaging Reagents
7.2.2. Fluorescent Imaging Reagents
7.2.3. MRI Contrasting Reagents
7.2.4. PET Radioactive Tracers
7.2.5. Ultrasound Contrasting Reagents
7.2.6. X-ray CT Contrasting Reagents
7.3. Software & Services
8. Preclinical Imaging Market, by Type
8.1. Introduction
8.2. Multimodal Systems
8.3. Standalone Imaging Systems
9. Preclinical Imaging Market, by Imaging Modality
9.1. Introduction
9.2. Magnetic Particle Imaging
9.3. Magnetic Resonance Imaging
9.4. Micro-Computed Tomography
9.5. Optical Imaging
9.6. Positron Emission Tomography
9.7. Single-Photon Emission Computed Tomography
10. Preclinical Imaging Market, by Applications
10.1. Introduction
10.2. Cardiology
10.3. Drug Development
10.4. Immunology & Inflammation
10.5. Infectious Diseases
10.6. Neurology
10.7. Oncology
11. Preclinical Imaging Market, by End Users
11.1. Introduction
11.2. Academic & Research Institutes
11.3. Contract Research Organizations
11.4. Pharmaceutical & Biotechnology Companies
12. Preclinical Imaging Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. Europe
12.4. North America
12.5. Latin America
12.6. Africa
12.7. Middle East
13. Preclinical Imaging Market, by Group
13.1. Introduction
13.2. NATO
13.3. G7
13.4. BRICS
13.5. European Union
13.6. ASEAN
13.7. GCC
14. Preclinical Imaging Market, by Country
14.1. Introduction
14.2. China
14.3. United States
14.4. Japan
14.5. India
14.6. Germany
14.7. United Kingdom
14.8. Australia
14.9. France
14.10. South Korea
14.11. Italy
14.12. Canada
14.13. Russia
14.14. Brazil
14.15. Mexico
14.16. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Advanced Molecular Vision, Inc.
16.2. Agilent Technologies, Inc.
16.3. Angstrom Advanced Inc.
16.4. Aspect Imaging Ltd.
16.5. AXT Pty Ltd
16.6. Berthold Technologies
16.7. Bruker Corporation
16.8. Cubresa, Inc.
16.9. Euro-BioImaging ERIC
16.10. FUJIFILM Holdings America Corporation
16.11. GE HealthCare Technologies Inc.
16.12. IVIM Technology Corp.
16.13. KUB Technologies, Inc.
16.14. LI-COR, Inc.
16.15. Mediso Ltd.
16.16. Milabs B.V.
16.17. Miltenyi Biotec GmbH
16.18. MR Solutions Ltd.
16.19. PerkinElmer Inc.
16.20. Revvity, Inc.
16.21. Scitech Pty Ltd
16.22. Siemens AG
16.23. TriFoil Imaging
16.24. United Imaging Healthcare Co., Ltd.
17. Key Experts
For more information about this report visit https://www.researchandmarkets.com/r/jnmpcs
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
